Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Observational Study for the Evaluation of Long-term Safety of Radium-223 Used for the Treatment of Metastatic Castration Resistant Prostate Cancer

Status: complete

Observational study in the routine clinical practice setting to evaluate the short and long term safety profile of Radium-223 in metastatic castration resistant prostate cancer patients and to evaluate the risk of developing second primary cancers.

Inclusion Criteria

Treatment decision to Radium-223 needs to be made independent from and before patient enrollment in the study
Histologically or cytologically confirmed castration resistant adenocarcinoma of the prostate with bone metastases
Signed informed consent

Exclusion Criteria

Previously treated with Radium-223 for any reason
Currently treated in clinical trials including other Radium-223 studies
Planned for the systemic concomitant use of other radiopharmaceuticals for treatment of prostate cancer or for other use

Have a question?
We're here to help

Chat with us: LiveHelp
Call us: 1-800-4-CANCER
(1-800-422-6237)

Which trials are right for you?

Use the checklist in our guide to gather the information you’ll need.